GlaxoSmithKline (GSK) Misses Q3 EPS by 60c; offers guidance

GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of GBP0.504, GBP0.60 worse than the analyst estimate of GBP1.10. Revenue for the quarter came in at GBP8.15 billion versus the consensus estimate of GBP9.31 billion.

GUIDANCE:

Turnover is expected to increase between 12 to 13 per cent (from 8 to 10 per cent)
Adjusted operating profit is expected to increase between 13 to 15 per cent (from 11 to 13 per cent)
Adjusted earnings per share is expected to increase between 17 to 20 per cent (from 14 to 17 per cent)

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform